OTX-TKI

Phase 3Small molecule

OTX-TKI is one of 18 small molecule programs targeting Neovascular Age-Related Macular Degeneration (nAMD). It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neovascular Age-Related Macular Degeneration (namd)Recruiting

Macular DegenerationActive, not recruiting

Neovascular Age-Related Macular Degeneration (namd)Phase 3

Recruiting

Macular DegenerationPhase 3

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Macular Degeneration

#DrugCompanyPhaseTrials

Vabysmo

Roche

Approved

3 2

Copaxone

Teva

Approved

—3

Iheezo

BB. Braun Medical Inc.

Approved

1 4

Avastin

Roche

Phase 3

7 5

Visudyne

BBausch Health Americas, Inc.

Approved

—6

Kenalog

BBausch Health Americas, Inc.

Approved

—7

Caverject

VViatris Specialty LLC

Approved

—8

OTX-TKI

OOcular Therapeutix, Inc.

Phase 3

1 9

Tiespectus

EEyeBiotech Ltd.

Phase 3

2 10

Faricimab Injection [vabysmo]

CCincinnati Eye Institute, Southwest Ohio

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Macular Degeneration

NCT06495918

Q3 2027

Phase 3Active, not recruiting

Age-Related Macular Degeneration

NCT06223958

Q3 2030

Phase 3Recruiting

Neovascular Age-Related Macular Degeneration (namd)

NCT07516132

Clinical

Trials by Indication[1]

Non-Proliferative Diabetic Retinopathy1 trial

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Unknown status·OOcular Therapeutix, Inc.·Phase 1·NCT05695417·21 enrolled

Macular Degeneration1 trial

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

Active, not recruiting·OOcular Therapeutix, Inc.·Phase 3·NCT06495918·825 enrolled

Age-Related Macular Degeneration1 trial

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration

Active, not recruiting·OOcular Therapeutix, Inc.·Phase 3·NCT06223958·344 enrolled

Treatment1 trial

CLN-0046: Treatment of AMD Subjects With OTX-TKI

Completed·OOcular Therapeutix, Inc.·Phase 1·NCT03630315·29 enrolled

Neovascular Age-Related Macular Degeneration (nAMD)1 trial

A Phase 3b, Multicenter, Open-Label, Extension Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Recruiting·OOcular Therapeutix, Inc.·Phase 3·NCT07516132·850 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for OTX-TKI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OTX-TKI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OTX-TKI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ocular Therapeutix, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOcular Therapeutix, Inc.

OTX-TKI

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q3 2030

Trials by Indication[1]

Non-Proliferative Diabetic Retinopathy1 trial

Macular Degeneration1 trial

Age-Related Macular Degeneration1 trial

Treatment1 trial

Neovascular Age-Related Macular Degeneration (nAMD)1 trial

References

Drug Info

Quick Facts

Related News